{"disease":{"id":"primary-immunodeficiency-pi","name":"primary immunodeficiency pi"},"drugs":{"marketed":[{"drug_id":"hyqvia","indication_name":"Primary Immunodeficiency (PI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HyQvia","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement","drug_class":"Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04864886","title":"Metabolic Profiling of Immune Responses in Immune-mediated Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02593188","title":"Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)","phase":"","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT03716700","title":"Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06565078","title":"A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05986734","title":"Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT00814320","title":"Gammagard Liquid and rHuPH20 in PID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT01218438","title":"Phase 2/3 Study of IGSC, 20% in PIDD","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT01175213","title":"Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05755035","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00157079","title":"Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06649643","title":"Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01412385","title":"Immune Globulin Subcutaenous (Human), 20%","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT01485796","title":"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT06076642","title":"A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04528355","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Paul Szabolcs","has_results":false},{"nct_id":"NCT00546871","title":"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT04691622","title":"Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT07017036","title":"Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Virchow Group","has_results":false},{"nct_id":"NCT03277313","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03116347","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT07004803","title":"Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency","phase":"NA","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Dr. Hatice Dönmez","has_results":false},{"nct_id":"NCT00161993","title":"Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06150534","title":"At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07261891","title":"Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"prof. dr. Rik Schrijvers","has_results":false},{"nct_id":"NCT04346108","title":"A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05150340","title":"A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05513586","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00782106","title":"Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT03330795","title":"Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false},{"nct_id":"NCT06955793","title":"Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Takeda","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}